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Smoking and non-alcoholic steatohepatitis (NASH):
The GREek Atorvastatin and Coronary heart
disease Evaluation (GREACE) trial
participated in advisory boards and trials sponsored by various
pharmaceutical companies (MSD, Genzyme, and Abbott).
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Letters to the EditorTo the Editor:
As the authors of the GREek Atorvastatin and Coronary heart dis-
ease Evaluation (GREACE) trial [1], we appreciate the comments
made by Babu et al. [2] and Zein et al. [3] regarding the role of
smoking on non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH). A few comments may be of
interest.
First, we assessed changes in vascular risk and the safety of
statins [1]. We could not analyse every possible relationship.
Second, in order to interpret the results of GREACE in terms of
NAFLD/NASH, there is a need to know how many patients were
smokers at the end of this trial. Essentially, the numbers were
similar to baseline values.
Third, it would be interesting to know the transaminase status
at the end of the GREACE study. In the NAFLD + not on statin
group, alanine aminotransferase (ALT) activity in smokers
(n = 19) was 70 ± 7 vs. 61 ± 9 U/L in non-smokers (n = 191),
p <0.0001. Therefore, smokers maintained a raised ALT activity
over the 3-year duration of the trial. In the NAFLD + on statin
group, ALT activity in smokers (n = 23) was 37 ± 6 vs. 37 ± 5 U/L
in non-smokers (n = 204), p = 0.10. This suggests that statins
improved ALT activity in smokers. These ﬁndings are limited
because they are based on a post hoc analysis and the number
of patients is small.
Our ﬁndings support the hypothesis discussed by Babu et al.
[2] and Zein et al. [3] regarding the adverse effect of smoking
on NAFLD and NASH. More work is needed in this ﬁeld.
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the manuscript. DPM has given talks, attended conferences, andDosage-sensitive network in polycystic kidney and liver
disease: Multiple mutations cause severe hepatic and
neurological complicationsTo the Editor:
Single kidney and liver cysts are common. If cysts occur multiply
and earlier in life, they are mostly inherited. Autosomal dominant
polycystic kidney disease (ADPKD) is one of the most common
genetic disorders with mutations in PKD1 or PKD2 and affects
10–15 million individuals worldwide [1]. Variable disease
expression even in the same family is incompletely understood,
some have intracranial aneurysms and most elderly patients
show liver cysts. Polycystic liver disease (ADPLD) is caused by a
dominant mutation in PRKCSH or SEC63, involved in posttransla-
tional translocation and quality control of proteins (such as the
ADPKD proteins) [2]. ADPLD patients can also harbour kidney476 Journal of Hepatology 20cysts. Morphologically, cysts are indistinguishable from those in
ADPKD. In mice, both diseases overlap not only clinically, but also
genetically and functionally, in line with a dosage-sensitive net-
work for polycystic liver and kidney disease [3].
We describe a family with liver and kidney cysts in which the
much more severely affected 39-year-old index patient (Fig. 1,
arrow) harbours a total of four mutant alleles in genes for PKD
and PLD, suggesting a dosage effect that may explain her severe
phenotype. Three aneurysms of the right middle cerebral artery
(MCA) led to subarachnoid haemorrhage at the age of 38 and
were surgically clipped. In addition, dissections of both carotid
arteries led to right-sided stenosis (Fig. 1). Massive liver disease12 vol. 57 j 467–477
